Mylan
- All
- News
- Videos
-
Biocon In Talks With Mylan To Merge Biosimilar Businesses: Report
Biocon will seek to hold a controlling majority stake in the merged entity and the companies will also look for an initial public offering (IPO).
-
US Body Warns Pharma Firm Mylan Over Quality In Telangana Plant: Report
Mylan NV received a warning from US regulators for failing to ensure key drug ingredients made at one of its plants in India were not contaminated.
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Report
Sources said the first batch of 10,000 vials had been printed with a price of Rs 4,000, Rs 800 below the cheapest option, launched by European competitor Mylan this week.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Mylan Labs Gets Nod To Manufacture Remdesivir For COVID-19 Patients
The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for ''restricted emergency use'' on hospitalised COVID-19 patients, a senior government official said on Thursday.
-
World Hepatitis Day: Mylan Launches Tablets For Treatment Of Hepatitis C
It's estimated that over 70 million people around the world have chronic Hepatitis C infection and nearly 400,000 people die each year from Hepatitis C-related liver diseases. Ahead of World Hepatitis Day the drug has now been launched to treat it.
-
Strides Shasun Rallies On Agreement To Settles Claims With Mylan
Strides had completed the sale of its Agila Specialties division to Mylan Inc for a total consideration of up to $1.75 billion in December 2013.
-
Biocon's Cancer Drug Accepted For Review, Shares Hit 52-Week High
Biocon shares jumped 5 per cent to their 52-week high on Friday after the drugmaker announced that the European regulator has accepted for review a breast cancer biosimilar jointly developed with Mylan. Biocon and American-Dutch Mylan are exclusive partners on a broad portfolio of biosimilars and insulin analogs.
-
European Medicines Agency Accepts Mylan, Biocon Biosimilar For Review
Mylan and Biocon anticipate that this may be the first marketing authorisation application (MAA) for a Trastuzumab biosimilar accepted by the EMA for review, it added.
-
US Patent Office Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma on Thursday said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
US Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
In Fight For GSK's Advair, Generic Firms Step Carefully On Price
Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.
-
Natco Pharma's Partner Mylan Inc Gets USFDA Approval For Cancer Drug
Natco Pharma's marketing partner Mylan Inc has received a tentative approval from the USFDA for abbreviated new drug application (ANDA) for Sorafenib tablets.
-
Natco Jumps 9% As Partner Mylan Inc Gets USFDA Nod
Natco Pharma shares surged nearly 9 per cent on Friday after the company said its marketing partner Mylan Inc has received tentative approval from the US health regulator for selling generic Sorafenib tablets, used for cancer treatment, in the American market.
-
Court Allows Biocon, Mylan To Continue To Manufacture Cancer Drugs
The Delhi High Court has allowed pharmaceutical firms Biocon Ltd and Mylan Pharmaceuticals Pvt Ltd to continue manufacturing and marketing their breast cancer drug under brand names CANMAb and HERTRAZ.
-
Biocon In Talks With Mylan To Merge Biosimilar Businesses: Report
Biocon will seek to hold a controlling majority stake in the merged entity and the companies will also look for an initial public offering (IPO).
-
US Body Warns Pharma Firm Mylan Over Quality In Telangana Plant: Report
Mylan NV received a warning from US regulators for failing to ensure key drug ingredients made at one of its plants in India were not contaminated.
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Report
Sources said the first batch of 10,000 vials had been printed with a price of Rs 4,000, Rs 800 below the cheapest option, launched by European competitor Mylan this week.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Mylan Labs Gets Nod To Manufacture Remdesivir For COVID-19 Patients
The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for ''restricted emergency use'' on hospitalised COVID-19 patients, a senior government official said on Thursday.
-
World Hepatitis Day: Mylan Launches Tablets For Treatment Of Hepatitis C
It's estimated that over 70 million people around the world have chronic Hepatitis C infection and nearly 400,000 people die each year from Hepatitis C-related liver diseases. Ahead of World Hepatitis Day the drug has now been launched to treat it.
-
Strides Shasun Rallies On Agreement To Settles Claims With Mylan
Strides had completed the sale of its Agila Specialties division to Mylan Inc for a total consideration of up to $1.75 billion in December 2013.
-
Biocon's Cancer Drug Accepted For Review, Shares Hit 52-Week High
Biocon shares jumped 5 per cent to their 52-week high on Friday after the drugmaker announced that the European regulator has accepted for review a breast cancer biosimilar jointly developed with Mylan. Biocon and American-Dutch Mylan are exclusive partners on a broad portfolio of biosimilars and insulin analogs.
-
European Medicines Agency Accepts Mylan, Biocon Biosimilar For Review
Mylan and Biocon anticipate that this may be the first marketing authorisation application (MAA) for a Trastuzumab biosimilar accepted by the EMA for review, it added.
-
US Patent Office Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma on Thursday said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
US Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
In Fight For GSK's Advair, Generic Firms Step Carefully On Price
Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.
-
Natco Pharma's Partner Mylan Inc Gets USFDA Approval For Cancer Drug
Natco Pharma's marketing partner Mylan Inc has received a tentative approval from the USFDA for abbreviated new drug application (ANDA) for Sorafenib tablets.
-
Natco Jumps 9% As Partner Mylan Inc Gets USFDA Nod
Natco Pharma shares surged nearly 9 per cent on Friday after the company said its marketing partner Mylan Inc has received tentative approval from the US health regulator for selling generic Sorafenib tablets, used for cancer treatment, in the American market.
-
Court Allows Biocon, Mylan To Continue To Manufacture Cancer Drugs
The Delhi High Court has allowed pharmaceutical firms Biocon Ltd and Mylan Pharmaceuticals Pvt Ltd to continue manufacturing and marketing their breast cancer drug under brand names CANMAb and HERTRAZ.
